The Gene Editing Delivery Summit will explore recent advances in gene editing delivery and novel gene editors that will make the dream of targeted in vivo gene editing a reality.
This is your one-stop-shop to unite with 80+ formulation and delivery experts from discovery to scale-up who understand that selecting and optimizing your delivery method of choice is not an afterthought. Don’t miss your chance to debate, discuss and share your delivery challenges to revolutionize the treatment of genetic diseases in this rapidly developing field.
Build your network and leave the Summit armed with insights to optimize targeted in vivo delivery of your gene editor of choice.
What's On?
15+ data driven case studies from the likes of Ascidian Therapeutics, Prime Medicine, and Tessera Therapeutics to gain practical delivery optimization to implement into your gene editing pipelines
2 deep diving workshops and practical sessions from Beam Therapeutics, Feldan Therapeutics, and Vesigen Therapeutics on novel delivery systems such as peptide shuttles, PNP, and exosomes, and pre-empting scale-up challenges in discovery to engage on the cutting edge of novel gene editing delivery strategies and accelerate into the clinic
Engaging panel and roundtable discussions led by the likes of Apellis Pharmaceuticals, Editas Medicine, and Sanofi to discuss hot topics such as the future opportunities of extra-hepatic delivery and the viability of viral vectors
7+ hours of networking including the invaluable speed networking sessions to establish new connections with the likes of AstraZeneca and Artisan Cells
Poster session to present your latest work on gene editing delivery and gain feedback from the community
Kelly Banas
Principal Investigator
ChristianaCare Gene Editing Institute
"I am looking forward to sharing and discussing our journey and challenges of bringing in vivo gene editing to the clinic with some of the top experts in the field."
“Delivery is the biggest challenge standing in the way of gene editing reaching its fullest potential and a problem that is beyond any one company. To reach success we require a large collective effort to tackle this problem and we inevitably rely on collaboration to better inform all of us where we can best deploy our efforts next.”
John Zuris
Director of Gene Editing Technologies
Editas Medicine
Kelly Banas
Principal Investigator
ChristianaCare Gene Editing Institute
"I am looking forward to sharing and discussing our journey and challenges of bringing in vivo gene editing to the clinic with some of the top experts in the field."
John Zuris
Director of Gene Editing Technologies
Editas Medicine
“Delivery is the biggest challenge standing in the way of gene editing reaching its fullest potential and a problem that is beyond any one company. To reach success we require a large collective effort to tackle this problem and we inevitably rely on collaboration to better inform all of us where we can best deploy our efforts next.”